Evoke Pharma (EVOK) began trading on the NASDAQ on 25 September 2013

Jan 2014 update

Description

Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The Company’s lead product candidate, EVK-001, is in late stage clinical testing. EVK-001 is a formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration. Gastroparesis is a condition of delayed gastric emptying in the absence of mechanical obstruction. Gastroparesis results in food remaining in the stomach for a longer time than normal, yielding a variety of symptoms.

Address

Suite 385, 12555 High Bluff Drive
SAN DIEGO, CA 92130
United States

Website 

http://www.evokepharma.com

Key stats and ratios

	Q2 (Jun '13)	2012
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-55.40%	-395.07%
Return on average equity	-	-
Employees	2